atai Life Sciences Announces R&D Day Agenda
20 October 2022 - 9:59PM
atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced the agenda for its virtual
R&D Day. During this event, management and scientific leaders
will provide a comprehensive review of atai’s diversified mental
health pipeline. The event will also provide updates on near-term
catalysts, with a focus on the upcoming Phase 2a topline results
for PCN-101 (R-ketamine) for treatment-resistant depression (TRD).
The event will be webcasted live on Tuesday, October 25, 2022,
at 12:00 PM ET. To access the presentation and webcast, please use
the following link or go to the events section of atai’s Investor
Relations page. Following the webcast, an archived version will
also be accessible in the events section of atai’s website where it
will be available for up to 90 days.
atai Life Sciences’ R&D Day agenda will include:
- atai Life Sciences R&D
Strategy and Pipeline Overview – Florian Brand, Co-Founder
and CEO
- Fireside Chat
- Topic: The Clinical and Regulatory
Landscape in Depression
- Moderator: Dr. Heather Berlin,
Neuroscientist, Clinical Psychologist, Associate Clinical Professor
of Psychiatry and Neuroscience at the Icahn School of Medicine at
Mount Sinai
- Participating KOLs:
- Gerard Sanacora, MD, PhD, Professor
of Psychiatry at Yale School of Medicine, Director of Yale’s
Depression Research Clinic, and Co-Director of Yale’s
Interventional Psychiatry Service
- Heddie Martynowicz, PhD, Regulatory
professional with 30 years of neuroscience drug development
experience at Janssen, Merck and BMS; President of Neokee Pharma
Consulting, LLC
- Program Updates:
Srinivas Rao, MD, PhD, Co-Founder and Chief Scientific Officer;
Rolando Gutierrez-Esteinou, MD, Chief Medical Officer; and Glenn
Short, PhD, Senior Vice President of Early Development
- PCN-101 – Context and discussion of
upcoming results of Phase 2a clinical trial of R-ketamine for
TRD
- COMP360 – Overview Phase 3 pivotal
program design of psilocybin therapy for TRD
- VLS-01 – Overview of Phase 1 trial
of a buccal thin film formulation of N,N-dimethyltryptamine (DMT)
for TRD in combination with atai’s digital therapeutic app
IDEA-1
- RL-007 – Preview of design of
the upcoming Phase 2b trial of RL-007 for cognitive impairment
associated with schizophrenia
- GRX-917 – Review of preliminary
pharmacokinetic and quantitative electroencephalogram (qEEG)
results from Phase 1 clinical trial of deuterated etifoxine for
generalized anxiety disorder
- KUR-101 – Review of positive initial
results from the single ascending dose component of Phase 1 trial
of oral formulation of deuterated mitragynine for opioid use
disorder
About atai Life Sciencesatai Life Sciences is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. Founded in 2018 as a response
to the significant unmet need and lack of innovation in the mental
health treatment landscape, atai is dedicated to acquiring,
incubating, and efficiently developing innovative therapeutics to
treat depression, anxiety, addiction, and other mental health
disorders.
By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies to achieve clinically meaningful and sustained behavioral
change in mental health patients.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. For more
information, please visit www.atai.life.
Forward-Looking StatementsThis presentation,
oral or written, may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any expressed or implied statements contained in the presentation
that are not statements of historical fact may be deemed to be
forward-looking statements. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation, the important
factors described in the section titled “Risk Factors” in our most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission (“SEC”), as updated by our subsequent filings
with the SEC, as such factors may be updated from time to time in
atai's other filings with the SEC. atai disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by applicable law.
Contact Information
Investor Contact:Stephen BardinChief Financial OfficerEmail:
IR@atai.life
Media Contact:Allan MalievskySenior Director of External
AffairsEmail: PR@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Apr 2023 to Apr 2024